Table 1.
Representative formulations for nanomedicine-mediated cancer starvation therapy described in this review.
Strategies | Materials | Therapeutics | Administration route | Treatments | Tumor models | Ref. |
---|---|---|---|---|---|---|
Antiangiogenesis-related cancer starvation therapy | αvβ3-integrin targeted perfluorocarbon NPs | Docetaxel-prodrug | i.v. injection | Antiangiogenesis therapy | Vx2 tumor bearing rabbits | 54 |
Chitosan NPs | Ursolic acid | Oral administration | Antiangiogenesis therapy | H22 tumor bearing mice | 145 | |
PGA-PTX-E-[c(RGDfK)2] | PTX | i.v. injection | Antiangiogenesis therapy | 4T1 tumor bearing mice | 57 | |
Recombinant human endostatin conjugated AuNPs | Recombinant human endostatin | Subcutaneous injection | Antiangiogenesis therapy | SW620 tumor bearing mice | 146 | |
MSNs | Tanshinone IIA | i.v. injection | Antiangiogenesis therapy | HT-29 tumor bearing mice | 53 | |
M-MSN@PEI-PEG-KALA NPs | anti-VEGF siRNA | i.v. injection | Antiangiogenic gene therapy | A549 tumor bearing mice | 43 | |
αvβ3-integrin-targeted lipid-encapsulated NPs | Fumagillin prodrug and zoledronic acid | i.v. injection | Dual antiangiogenic therapy | Vx2 tumor bearing rabbits | 55 | |
Thiolated-glycol chitosan formed NPs | Bevacizumab and poly- anti-VEGF siRNA | i.v. injection | Dual antiangiogenic therapy | A431 tumor bearing mice | 65 | |
Polymer-lipid hybrid NPs | DOX and MMC | i.v. injection | Antiangiogenesis therapy and chemotherapy | MDA-MB 435/LCC6/WT tumor bearing mice and MDA-MB 435/LCC6/MDR1 tumor bearing mice | 34 | |
pH and thermo-responsive MSNs | DOX and MTX | i.v. or oral administration | Antiangiogenesis therapy and chemotherapy | OSCC tumor bearing mice | 62 | |
PEGylated lipid bilayer-supported MSNs | AXT and CST | i.v. injection | Antiangiogenesis therapy and chemotherapy | SCC7 tumor bearing mice | 147 | |
MMP-2 responsive mPEG-peptide diblock copolymer (PPDC) NPs | CPT and Sorafenib | i.v. injection every | Antiangiogenesis therapy and chemotherapy | HT-29 tumor bearing mice | 63 | |
pH-sensitive poly(beta-amino ester) copolymer NPs | DOX and Cur | i.v. injection | Antiangiogenesis therapy and chemotherapy | SMMC 7721 tumor bearing mice | 64 | |
Captopril-polyethyleneimine conjugated AuNPs | Captopril and siRNA | i.v. injection | Antiangiogenesis and gene therapy | MDA-MB-435 tumor bearing mice | 66 | |
Calcium phosphate NPs | anti-VEGF shRNA and yCDglyTK | Intraperitoneal or intratumoral administration | Antiangiogenic gene therapy and suicide gene therapy | SGC7901 tumor bearing mice | 67 | |
CTX-coupled SNALP-formulated anti-miR-21 oligonucleotides | CTX and anti-miR-21 | i.v. or oral administration | Antiangiogenesis therapy and gene therapy | GBM tumor bearing mice | 68 | |
RhoJ antibody modified Au@I NPs | RhoJ antibody | i.v. injection | Antiangiogenesis therapy and radiotherapy | Patient-derived tumor xenografts | 61 | |
AuNPs | anti-VEGF siRNA | Intratumoral injection and laser irritation (655 nm) | Antiangiogenic gene therapy and photothermal therapy | PC-3 tumor bearing mice | 31 | |
Near infrared probe iron oxide NPs | Bevacizumab | i.v. injection | Antiangiogenesis therapy and imaging | 4T1 tumor bearing mice | 58 | |
Sorafenib and Ce6 formed carrier-free NPs | Sorafenib and Ce6 | i.v. injection and laser irritation (660 nm) | Antiangiogenesis therapy and photodynamic therapy | HSC3 tumor bearing mice | 72 | |
VDAs-based cancer starvation therapy | ||||||
DOX-PLGA-conjugate NPs | Free CA4 and DOX | i.v. injection | Starvation therapy and chemotherapy | Lewis lung carcinoma xenografts and B16F10 tumor bearing mice | 23 | |
LyP-1 coated liposomes | Free Ombrabulin and DOX | i.v. injection | Starvation therapy and chemotherapy | MDA-MB-435 tumor bearing mice | 74 | |
Poly(L-glutamic acid)-g-mPEG NPs | Free CA4P and CDDP | i.v. injection | Starvation therapy and chemotherapy | MDA-MB-435 tumor bearing mice | 75 | |
A15-PGA-CDDP NPs | Free DMXAA and CDDP | i.v. injection | Starvation therapy and chemotherapy | C26 tumor bearing mice | 42 | |
CA4-NPs | CA4 | i.v. injection | Starvation therapy | C26 tumor bearing mice | 28 | |
mPEG-b-PHEA-DMXAA conjugate NPs | DMXAA and DOX | i.v. injection | Starvation therapy and chemotherapy | MCF-7 tumor bearing mice | 76 | |
CA4-NPs | CA4 and TPZ | i.v. injection | Starvation therapy and chemotherapy | 4T1 tumor bearing mice | 27 | |
CA4-NPs and MMP9-DOX-NPs | CA4 and DOX | i.v. injection | Starvation therapy and chemotherapy | 4T1 and C26 tumor bearing mice | 78 | |
Vascular blockade-induced cancer starvation therapy | CREKA modified IONPs and CRKDKC modified iron oxide nanoworms | Two tumor-homing peptide of CREKA and CRKDKC | i.v. injection | Starvation therapy | 22Rv1 tumor bearing mice | 88 |
DNA nanorobots | Thrombin | i.v. injection | Starvation therapy | MDA-MB-231 tumor bearing mice | 26 | |
PVP-modified Mg2Si NPs | Mg2Si | Intratumoral injection | Starvation therapy | 4T1 tumor bearing mice | 11 | |
TPZ-MNPs | Mg2Si and TPZ | Intratumoral injection | Starvation therapy and hypoxia-activated chemotherapy | 4T1 tumor bearing mice | 38 | |
GOx-mediated cancer starvation therapy | GOx-MnO2@HA NPs | GOx and MnO2 | Intratumoral injection | Starvation therapy | CT-26 tumor bearing mice | 98 |
Large pore-sized dendritic silica NPs | GOx and Fe3O4 NPs | Intratumoral or i.v. injection | Starvation therapy and oxidation therapy | 4T1 and U87 tumor xenografts | 106 | |
PEG-b-P(PBEM-co-PEM) NPs | GOx and QM | i.v. injection | Starvation therapy and oxidation therapy | A549 tumor bearing mice | 101 | |
Poly(FBMA-co-OEGMA) nanogels | GOx | Intratumoral injection | Starvation therapy and oxidation therapy | C8161 tumor bearing mice | 96 | |
Fe5C2-GOx@MnO2 NCs | GOx, Fe5C2 and MnO2 | i.v. injection | Starvation therapy and oxidation therapy | U14 and 4T1 tumor bearing mice | 107 | |
GOx-CPO@ZIF-8@NM NPs | GOx and CPO | i.v. injection | Starvation therapy and oxidation therapy | 4T1 tumor bearing mice | 109 | |
ATP-responsive GOx@ZIF@MPN NPs | GOx and Fe(III)/Fe(II) | Intratumoral injection e | Starvation therapy and oxidation therapy | 4T1 tumor bearing mice | 108 | |
FDMSNs@GOx@HA | GOx and Ferrocene | i.v. injection | Starvation therapy and oxidation therapy | HeLa tumor bearing mouse | 148 | |
GOx@PCPT-NR | GOx and CPT prodrug | i.v. injection | Starvation therapy and chemotherapy | A549 tumor bearing mice | 41 | |
Mem@GOx@ZIF-8@BDOX) NPs | GOx and BDOX | i.v. injection | Starvation therapy and chemotherapy | 4T1 tumor bearing mice | 99 | |
MSNs-GOx/PLL/HA | GOx and PTX | i.v. injection | Starvation therapy and chemotherapy | HepG2 tumor bearing mice | 149 | |
Yolk-shell tetrasulfide bond bridged dendritic MONs | GOx and AQ4N | Intratumoral injection o | Starvation therapy and hypoxia-activated chemotherapy | 4T1 tumor bearing mice | 33 | |
TGZ@eM NRs | GOx and TPZ | i.v. injection | Starvation therapy and hypoxia-activated chemotherapy | CT26 tumor bearing mice | 13 | |
HA-coated CaCO3 NPs | GOx and TPZ | i.v. injection | Starvation therapy and hypoxia-activated chemotherapy | CT26 tumor bearing mice | 100 | |
Liposomes | GOx and AQ4N | Intratumoral injection | Starvation therapy and hypoxia-activated chemotherapy | 4T1 tumor bearing mice | 30 | |
BCETPZ@(GOx+CAT) | GOx, CAT and TPZ | i.v. injection | Starvation therapy and hypoxia-activated chemotherapy | EMT-6 tumor bearing mice | 94 | |
GOx conjugated polymer dots | GOx | Intratumoral injection and laser irritation (460 nm) | Starvation therapy and photodynamic therapy | MCF-7 tumor bearing mice | 115 | |
Mem@catalase@GOx@PCN-224 bioreactor | GOx, CAT and TCPP | i.v. injection and laser irritation (660 nm) | Starvation therapy and photodynamic therapy | 4T1 tumor bearing mice | 44 | |
HMSNs | GOx and Ce6 | i.v. injection | Starvation therapy and photodynamic therapy | B16F10 metastatic tumor bearing mice | 32 | |
Hollow-MnO2-GOx-Ce6@CM | GOx, MnO2 and Ce6 | i.v. injection and laser irritation (655 nm) | Starvation therapy and photodynamic therapy | B16F10 tumor bearing mice | 150 | |
rMGB | GOx, MnO2 and Ce6 | i.v. injection and laser irridation (660 nm) | Starvation therapy and photodynamic therapy | 4T1 cancer bearing mice | 120 | |
PEGylate HA-functionalized PHPBNs | GOx | i.v. injection and NIR laser irritation (808 nm) | Starvation therapy and photothermal therapy | HepG2 tumor bearing mice | 121 | |
BSA-directed two-dimensional MnO2 nanosheet | MnO2 | i.v. injection and NIR laser irritation (808 nm) | Starvation therapy and photothermal therapy | U87MG tumor bearing mice | 122 | |
GOx-conjugated silver nanocubes | GOx and Ag ions | Intratumoral injection | Starvation therapy and metal ion therapy | 4T1 tumor bearing mice | 113 | |
HMONs | L-Arg and GOx | Intratumoral injection | Starvation therapy and gas therapy | U87MG tumor bearing mice | 46 | |
CMSNs | GOx and anti-PD-1 | i.v. injection | Starvation therapy and immunotherapy | B16F10 tumor bearing mice | 47 | |
Fe3O4@PPy@GOx NCs. | GOx, Fe3O4 NPs and PPy | i.v. injection and NIR laser irradiation (808 or 1064 nm) | Starvation therapy, oxidation therapy and photodynamic therapy | 4T1 tumor bearing mice | 45 | |
CPT@MOF(Fe)-GOx | GOx, Fe3+ and CPT | Intratumoral injection | Starvation therapy, oxidation therapy and chemotherapy | HeLa tumor bearing mice | 151 | |
MGH nanoamplifier | GOx and MIL-100 | i.v. injection, NIR laser irradiation (808 nm) | Starvation therapy, oxidation therapy, photothermal therapy and imaging | 4T1 tumor bearing mice | 110 | |
Other strategies for cancer starvation therapy | HDL-AuNPs | HDL | i.v. injection | Starvation therapy | B-cell lymphoma xenografts | 39 |
HDL-AuNPs | HDL | i.v. injection | Starvation therapy and immunotherapy | LLC tumor bearing mice and melanoma metastatic lung colonization mice model | 140 | |
CHC-PZM@HA | CHC and PZM | i.v. injection, laser irradiation (660 nm) | Starvation therapy and photodynamic therapy | CT26 tumor bearing mice | 40 | |
Mn-D@BPFe-A NPs | DOX, Fe3+ | Starvation therapy, chemotherapy and photodynamic therapy | HepG2 tumor bearing mice | 141 |